12.00
+0.25(+2.13%)
Currency In GBp
Address
Unit 202 Bellhouse Building
Oxford, OX4 4GD
United Kingdom of Great Britain and Northern Ireland
Phone
44 18 6558 2066
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
February 12, 2010
| Name | Title | Pay | Year Born |
| Phillip John L'Huillier | Chief Executive Officer & Director | 391,966 | 1962 |
| Sathijeevan Nirmalananthan | Chief Financial Officer, Company Secretary & Director | 267,750 | 1986 |
| Lindy Gillian Durrant | Chief Scientific Officer, Director & Founder | 386,797 | 1957 |
| Callum Scotthasbeen | Senior Vice President of Development | 0 | N/A |
| Mandeep Sehmi | Head of Business Development | 0 | N/A |
| Nermeen Varawalla | Chief Medical Officer | 0 | 1962 |
| Samantha Paston | Head of Translational Research | 0 | N/A |
| Shamim Kazmi Stokes | Head of Programme Management | 0 | N/A |
| Alex Hayward | Head of Finance | 0 | N/A |
| Philip Angell-Manning | Head of CMC | 0 | N/A |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.